A Phase 2 interventional study of REGN5381 and Placebo in Heart Failure, sponsored by Regeneron Pharmaceuticals. Terminated at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.
Among the 197 studies in Heart Failure with a site in Belgium, this one is the 105th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2024, is one of 23 in phase 2, and was the 176th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Belgium, United States, France and 7 more countries
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages up to 18
Fondazione Don Carlo Gnocchi ETS · Sites in Belgium, Italy, Portugal and 1 more country
Ages 18+
Ziekenhuis Oost-Limburg · Sites in Belgium
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 27 · Phase 3 44 · Phase 4 9
First in 1983; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 262 across the 155 interventional studies, 450 across the 42 observational. Of the 137 that completed or were terminated, 58 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 197 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06661876Universitaire Ziekenhuizen KU LeuvenCardiac RadiothErapy For hEart faiLure | 2026-12-31 |
| NCT07823998Jean-Benoît Le Polain de WarouxCoffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD | 2027-04 |
| NCT07556588XVIVO PerfusionXVIVO Heart Transplant Study in Clinical Practice | 2027-05-15 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 197 studies in Heart Failure with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
Enrollment for the Part A2 low eGFR cohort has been closed
Key Inclusion Criteria
Sacubitril-valsartan treatment:
a. Treatment with sacubitril-valsartan at screening and at baseline permitted in Part A2 sacubitril-valsartan cohort and in Part B if supported by safety data from the Part A2 sacubitril-valsartan cohort as described in the protocol
Estimated (eGFR) levels:
Key Exclusion Criteria
Note: Other protocol-defined inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Drug: Placebo
Single ascending dose cohort. Note: This group has been closed
Drug: REGN5381
Single ascending dose cohort. Note: This group has been closed
Drug: REGN5381
Note: This group has been closed
Drug: Placebo
Drug: REGN5381
Drug: REGN5381
Drug: Placebo
Single dose intravenous (IV) infusion
Single dose IV infusion
Change from baseline in circulating N-Terminal pro-Brain Natriuretic Peptide (NTproBNP)
Time frame: Day 8
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Through week 16
Severity of TEAEs
Time frame: Through week 16
Change from baseline in circulating NT-proBNP
Time frame: Week 2
Change from baseline in circulating NT-proBNP
Time frame: Week 3
Change from baseline in circulating NT-proBNP
Time frame: Week 4
Change from baseline in circulating NT-proBNP
Time frame: Up to week 16
Change from baseline in Systolic Blood Pressure (SBP)
Time frame: Each visit through week 16
Change from baseline in Diastolic Blood Pressure (DBP)
Time frame: Each visit through week 16
Change from baseline in Mean Arterial Pressure (MAP)
Time frame: Each visit through week 16
Change from baseline in Heart Rate (HR)
Time frame: Each visit through week 16
Concentrations of REGN5381 in serum
Time frame: Through week 16
Incidence of Anti-Drug Antibodies (ADAs) to REGN5381
Time frame: Through week 16
Magnitude of ADAs to REGN5381
Time frame: Through week 16
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Sep 2025, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vixticibart